The EU Commission clears the acquisition of a pharmaceutical company by a global conglomerate subject to commitment that clinical development of innovative insomnia drugs will not be adversely affected by the merger (Johnson & Johnson / Actelion)

J&J/Actelion - falling asleep fast and deeply while staying fully awake on innovation * In a nutshell: The Commission found competitive concerns due to the combination of two development programmes for insomnia drugs, currently in Phase II of clinical trials. These pipeline drugs are based on a novel mechanism of action, orexin-antagonists, which has already shown potential for having less side effects and reduced risk of dependency compared to existing insomnia treatments. Due to the lack of competing pipeline programmes, the transaction brought about a risk for innovation competition, if, post-merger, J&J were to discontinue, reorient or delay one of the parties’ pipelines. J&J offered two complementary sets of tailor-made remedies to address those concerns. Overview

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • DG COMP (Brussels)
  • Spanish Ministry of Economy, Industry and Competitiveness (Madrid)
  • DG COMP (Brussels)

Quotation

Rositsa Pencheva, Noa Laguna-Goya, Marion Bailly, The EU Commission clears the acquisition of a pharmaceutical company by a global conglomerate subject to commitment that clinical development of innovative insomnia drugs will not be adversely affected by the merger (Johnson & Johnson / Actelion), 9 June 2017, e-Competitions June 2017, Art. N° 86509

Visites 322

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues